Evidence map›Paper›PMID 32453913›Full record

Trial reportClinical and translational science2020

Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.

Minna Lehtisalo, Jenni E Keskitalo, Aleksi Tornio, Outi Lapatto-Reiniluoto, Feng Deng, Taina Jaatinen, Jenni Viinamäki, Mikko Neuvonen, Janne T Backman, Mikko Niemi

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Drug metabolism and drug transport of the 100 most prescribed oral drugs.Basic & clinical pharmacology & toxicology · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Minna LehtisaloDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Jenni E KeskitaloDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Aleksi TornioDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Outi Lapatto-ReiniluotoDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Feng DengDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Taina JaatinenThe Finnish Red Cross Blood Service, Helsinki, Finland.
Jenni ViinamäkiDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Mikko NeuvonenDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Janne T BackmanDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Mikko NiemiDepartment of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
University of Helsinki · FIHelsinki University Hospital · FIFinnish Red Cross · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xanthine oxidase inhibitors febuxostat and allopurinol are commonly used in the treatment of gout. Febuxostat inhibits the breast cancer resistance protein (BCRP) in vitro. Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. In this study, we investigated possible effects of febuxostat and allopurinol on rosuvastatin pharmacokinetics. In a randomized crossover study with 3 phases, 10 healthy volunteers ingested once daily placebo for 7 days, 300 mg allopurinol for 7 days, or placebo for 3 days, followed by 120 mg febuxostat for 4 days, and a single 10 mg dose of rosuvastatin on day 6. Febuxostat increased the peak plasma concentration and area under the plasma concentration-time curve of rosuvastatin 2.1-fold (90% confidence interval 1.8-2.6; P = 5 × 10

Indexed as

Administration, OralAdultAllopurinolArea Under CurveATP Binding Cassette Transporter, Subfamily G, Member 2Cross-Over StudiesDrug InteractionsFebuxostatFemaleHealthy VolunteersHumansIntestinal MucosaIntestine, SmallMaleNeoplasm ProteinsRosuvastatin CalciumABCG2 protein, humanAllopurinolATP Binding Cassette Transporter, Subfamily G, Member 2FebuxostatNeoplasm ProteinsRosuvastatin Calcium

Identifiers

PMID32453913
PMCPMC7719384
OpenAlexW3032314402

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.